Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immuron Limited ( (AU:IMC) ) has shared an update.
Immuron Limited has announced the issuance of 314,843 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant provisions. This move is part of the company’s ongoing efforts to maintain transparency and adhere to regulatory requirements, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases.
Average Trading Volume: 1,056,012
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$12.68M
See more data about IMC stock on TipRanks’ Stock Analysis page.